Nuheara Brings ADCO On Board as New Distributor in The United States

nuheara limited

Nuheara Limited (ASX: NUH) takes a step further in the United States as the company adds ADCO Medical suppliers as the latest distributor for selling its IQbuds medical devices. Nuheara and ADCO would work together to enhance the supply of hearing devices in the United States. Nuheara would primarily be focused on promoting its advanced BOOST earbud product for the patients who suffer from mild to medium hearing loss.

ADCO holds strategic importance for Nuheara as former is an authorized General Service Administration contract holder concerned with supplying the audiological solutions to the United States Government. The United States Department of Veterans Affairs supplies close to 25% of all hearing devices in the country and employs maximum audiologists to provide services across 400 sites. Nuheara would benefit because ADCO is a certified hearing assistance device supplier to the VA department. In the context of the recent development, Justin Miller, CEO of Nuheara stated that the company is determined to renovate the way people know hearing solutions. He added that Nuheara is committed to offering an affordable solution to those in need. He further added that the United States has demonstrated the strong commitment to improving the accessibility and affordability in the hearing solution industry. It was in the same breath that the government passed Over-The-Counter legislation in 2017. The current environment is conducive for the company as it stands to benefit from the association with quality partners such as ADCO. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

In another development, Nuheara also received an Export Market Development grant worth $146K. The company announced that its products are now eligible for Export Marketing Development Grants support from January 2016.

Nuheara Limited was trading at $0.089, down 6.316% (AEST: 04:00 p.m.) in today’s session and has the market capitalization of circa $84.69 Mn as on 06 September 2018.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report